Table 2:

Morbidity and mortality after Fontan completion

All Fontan patients (n = 217)Era I (n = 18)Era II (n = 199)
Fontan failure24 (11.1%)5 (27.8%)19 (9.5%)
 Death7 (3.2%)2 (11.1%)5 (2.5%)
  Early2 (0.9%)2 (11.1%)0 (0%)
  Late5 (2.3%)0 (0%)5 (2.5%)
 Heart transplantation5 (2.3%)0 (0%)5 (2.5%)
 Protein-losing enteropathy8 (3.7%)2 (11.1%)6 (3%)
 Plastic bronchitis1 (0.5%)0 (0%)1 (0.5%)
 NYHA III/IV3 (1.4%)1 (5.6%)2 (1%)
All Fontan patients (n = 217)Era I (n = 18)Era II (n = 199)
Fontan failure24 (11.1%)5 (27.8%)19 (9.5%)
 Death7 (3.2%)2 (11.1%)5 (2.5%)
  Early2 (0.9%)2 (11.1%)0 (0%)
  Late5 (2.3%)0 (0%)5 (2.5%)
 Heart transplantation5 (2.3%)0 (0%)5 (2.5%)
 Protein-losing enteropathy8 (3.7%)2 (11.1%)6 (3%)
 Plastic bronchitis1 (0.5%)0 (0%)1 (0.5%)
 NYHA III/IV3 (1.4%)1 (5.6%)2 (1%)

Data are presented as frequencies (percentages).

NYHA: New York Heart Association Functional Classification.

Table 2:

Morbidity and mortality after Fontan completion

All Fontan patients (n = 217)Era I (n = 18)Era II (n = 199)
Fontan failure24 (11.1%)5 (27.8%)19 (9.5%)
 Death7 (3.2%)2 (11.1%)5 (2.5%)
  Early2 (0.9%)2 (11.1%)0 (0%)
  Late5 (2.3%)0 (0%)5 (2.5%)
 Heart transplantation5 (2.3%)0 (0%)5 (2.5%)
 Protein-losing enteropathy8 (3.7%)2 (11.1%)6 (3%)
 Plastic bronchitis1 (0.5%)0 (0%)1 (0.5%)
 NYHA III/IV3 (1.4%)1 (5.6%)2 (1%)
All Fontan patients (n = 217)Era I (n = 18)Era II (n = 199)
Fontan failure24 (11.1%)5 (27.8%)19 (9.5%)
 Death7 (3.2%)2 (11.1%)5 (2.5%)
  Early2 (0.9%)2 (11.1%)0 (0%)
  Late5 (2.3%)0 (0%)5 (2.5%)
 Heart transplantation5 (2.3%)0 (0%)5 (2.5%)
 Protein-losing enteropathy8 (3.7%)2 (11.1%)6 (3%)
 Plastic bronchitis1 (0.5%)0 (0%)1 (0.5%)
 NYHA III/IV3 (1.4%)1 (5.6%)2 (1%)

Data are presented as frequencies (percentages).

NYHA: New York Heart Association Functional Classification.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close